Analyst Ratings For GE HealthCare Techs
Portfolio Pulse from Benzinga Insights
GE HealthCare Techs (NASDAQ:GEHC) has received mixed analyst ratings over the last three months, with a recent shift towards a more bullish outlook. The average 12-month price target has been adjusted to $79.00, down from $86.00, reflecting a decrease of 8.14%. Analysts from Mizuho, Morgan Stanley, Jefferies, and UBS have updated their ratings and price targets, indicating varied expectations for the company's performance. GE HealthCare Techs, a leader in medical technology and diagnostics, has shown solid revenue growth but faces challenges in net margin, ROA, and debt management.
February 07, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GE HealthCare Techs has seen a recent shift towards a more bullish sentiment among analysts, with an updated average 12-month price target of $79.00. Despite solid revenue growth, the company faces challenges in net margin, ROA, and debt management.
The shift towards a more bullish sentiment among analysts, despite the decrease in the average price target, suggests a positive outlook for GEHC's stock in the short term. The solid revenue growth indicates strong business performance, but challenges in net margin, ROA, and high debt-to-equity ratio could pose risks. The mixed analyst ratings and adjustments in price targets reflect ongoing market reassessment of GEHC's future performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100